Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A urethra cancer that involves the penis.
Biomarker and diagnostic research for penile urethral cancer has been reported in the published literature.
No clinical trials have been registered for penile urethral cancer.
189 publications have been identified in PubMed for penile urethral cancer. Research spans Clinical Trial Publication (30%), Case Report / Case Series (25%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 56 | 30% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 11:56 AM UTC
48 |
25% |
Research summaries | 28 | 15% |
Disease patterns and progression | 23 | 12% |
Testing and diagnosis research | 15 | 8% |
Laboratory research | 15 | 8% |
Other research | 4 | 2% |
DI Trapani E (2026). [PMID: 42023746](https://pubmed.ncbi.nlm.nih.gov/42023746/). *Minerva Urol Nephrol*. [Review / Meta-Analysis]
Ando S (2026). [PMID: 42205081](https://pubmed.ncbi.nlm.nih.gov/42205081/). *Int J Urol*. [Diagnostic / Biomarker]
Yildiz AK (2026). [PMID: 40877645](https://pubmed.ncbi.nlm.nih.gov/40877645/). *Int Urol Nephrol*. [Clinical Trial Publication]
Zhu YL (2026). [PMID: 41501738](https://pubmed.ncbi.nlm.nih.gov/41501738/). *BMC Urol*. [Clinical Trial Publication]
Kalinowski P (2026). [PMID: 41522806](https://pubmed.ncbi.nlm.nih.gov/41522806/). *Oncol Lett*. [Case Report / Case Series]
Mennes J (2026). [PMID: 41432584](https://pubmed.ncbi.nlm.nih.gov/41432584/). *BJU Int*. [Clinical Trial Publication]
Ratnakumaran R (2026). [PMID: 39862896](https://pubmed.ncbi.nlm.nih.gov/39862896/). *Int J Radiat Oncol Biol Phys*. [Clinical Trial Publication]
Garaz R (2026). [PMID: 41904097](https://pubmed.ncbi.nlm.nih.gov/41904097/). *Urol Oncol*. [Review / Meta-Analysis]
Nguyen L (2026). [PMID: 41412436](https://pubmed.ncbi.nlm.nih.gov/41412436/). *Radiother Oncol*. [Epidemiology / Natural History]
Pagonis K (2026). [PMID: 41818410](https://pubmed.ncbi.nlm.nih.gov/41818410/). *Prostate*. [Epidemiology / Natural History]
AI-curated news mentioning penile urethral cancer
Updated Sep 18, 2026
A phase II trial, MH-Penile-002, investigates a neoadjuvant treatment combining an anti-EGFR antibody-drug conjugate with a PD-1 inhibitor for penile cancer. This study focuses on patients facing challenges with penile preservation or regional lymph node metastasis.
The PERICLES trial identifies pre-existing immunity and high-risk HPV status as key factors influencing immunotherapy response in advanced penile cancer. These findings could guide future treatment strategies and patient selection.
A recent study highlights the epidemiological trends in penile cancer and discusses the evolving role of dynamic sentinel lymph node biopsy in its management. This research provides insights into the changing landscape of diagnosis and treatment for this rare disease.